Golar LNG Limited Announces Proposed Offering of $350 Million of Convertible Senior Notes due 2022
Feb 13, 2017 21:04 pm UTC| Business
Hamilton, Bermuda - February 13, 2017- Golar LNG Limited (the "Company") (NASDAQ:GLNG) announces today that it intends to offer, subject to market and other conditions, $350 million aggregate principal amount of...
Forward Reports Fiscal 2017 First Quarter Results
Feb 13, 2017 21:03 pm UTC| Business
WEST PALM BEACH, Fla., Feb. 13, 2017 -- Forward Industries, Inc. (NASDAQ:FORD), a designer and distributor of custom carry and protective solutions, today announced financial results for its first fiscal quarter ended...
Feb 13, 2017 21:02 pm UTC| Business
NEW YORK, Feb. 13, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased FXCM, Inc....
Corium Reports First Quarter Fiscal 2017 Financial Results
Feb 13, 2017 21:02 pm UTC| Business
MENLO PARK, Calif., Feb. 13, 2017 -- Corium International,Inc.(Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products,...
Cutera Reports Fourth Quarter and Full-Year 2016 Record Revenue and Financial Results
Feb 13, 2017 21:01 pm UTC| Business
BRISBANE, Calif., Feb. 13, 2017 -- Cutera, Inc. (NASDAQ:CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today reported financial results for...
Feb 13, 2017 21:01 pm UTC| Business
SaaS License Revenue Increases 11.3% Company Generates Positive Adjusted EBITDABURLINGTON, Mass., Feb. 13, 2017 -- Bridgeline Digital, Inc. (NASDAQ:BLIN), The Digital Engagement Company™, today announced financial...
Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
Feb 13, 2017 21:01 pm UTC| Business
ATLANTA, Feb. 13, 2017 -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic...